Loading...
XSHG
603367
Market cap881mUSD
Jul 10, Last price  
13.68CNY
1D
3.56%
1Q
-16.28%
IPO
-25.93%
Name

Cisen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603367 chart
P/E
14.70
P/S
1.80
EPS
0.93
Div Yield, %
3.09%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-1.28%
Revenues
3.44b
-13.48%
1,531,420,9852,051,722,0592,205,981,8822,388,354,5632,496,971,9882,564,801,1052,962,516,5243,808,078,4264,112,785,5093,674,158,4743,782,592,6344,066,088,4474,462,348,6353,981,572,2323,444,716,683
Net income
421m
-17.22%
236,929,557283,857,308208,298,939220,152,041246,854,937246,881,906367,221,929503,544,867514,580,080438,784,468334,146,426349,958,588521,338,338508,906,200421,249,422
CFO
619m
+8.52%
76,281,41433,086,38281,260,05527,538,117266,243,874291,972,115439,607,583406,675,789181,263,844431,007,158233,598,087258,345,605451,240,761570,848,680619,490,540
Dividend
Oct 13, 20250.188 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cisen Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, manufacturing and distributing a diverse portfolio of chemical drug preparations and healthcare products to both domestic and international markets. Founded in 1998 and based in Jining, People's Republic of China, the company offers an extensive range of chemical drug solutions. These include medications for liver diseases, antitumor and supportive treatments, nutritional supplements, contrast agents, antibiotics, digestive system remedies, polypropylene ampoules, and topical preparations. Additionally, their product line encompasses sedation and anesthesia agents, cardiovascular drugs, treatments for cough and asthma, immunomodulators, and various infusion and therapeutic infusion products. The company officially changed its name to Cisen Pharmaceutical Co., Ltd. in 2011, having previously operated as Shandong Lukang Cisen Pharmaceutical Co., Ltd.
IPO date
Sep 29, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT